CHAD Therapeutics Previews New Oxygen Therapeutic Device; First in a Planned Family of Oxygen Therapeutic Devices Employing CHAD's Proprietary Technologies.Business Editors/Health/Medical Writers Medtrade Spring CHATSWORTH, Calif.--(BUSINESS WIRE)--March 17, 2004 CHAD Therapeutics, Inc. (ASE (Adaptive Server Enterprise) A relational DBMS from Sybase that runs on Windows NT/2000, Linux and a variety of Unix platforms. ASE is a comprehensive and robust data management product with a long history dating back to the late 1980s. :CTU CTU Colorado Technical University CTU Czech Technical University in Prague CTU Counter Terrorist Unit CTU Clinical Trials Unit CTU Catholic Theological Union CTU Chicago Teachers Union CTU Computer Training Unit CTU Control Unit ) announced today that it will preview its new SAGE(TM) Oxygen Therapeutic Device at the Medtrade Spring trade show in Las Vegas Las Vegas (läs vā`gəs), city (1990 pop. 258,295), seat of Clark co., S Nev.; inc. 1911. It is the largest city in Nevada and the center of one of the fastest-growing urban areas in the United States. . SAGE is SAGE I Stratospheric Aerosol and Gas Experiment I the first in a planned family of oxygen therapeutic devices that use CHAD's proprietary technologies to sense a patient's movements and automatically adjust the rate of oxygen delivery to reduce the risk of desaturation desaturation /de·sat·u·ra·tion/ (de-sach?ah-ra´shun) the process of converting a saturated compound to one that is unsaturated, such as the introduction of a double bond between carbon atoms of a fatty acid. as activity increases. Thomas E. Jones, Chief Executive Officer, said, "CHAD's new SAGE Oxygen Therapeutic Device combines the industry's first truly dynamic delivery technology with the proven oxygen sensor An oxygen sensor is an electronic device that measures the proportion of oxygen (O2) in the gas or liquid being analyzed. It was developed by Robert Bosch GmbH during the late 1960s under supervision by Dr. Günter Bauman. technology in our OXYMATIC(TM) 400 series conserver to create a therapeutic device that addresses the common problem of oxygen desaturation, which causes a patient to feel weak and out of breath when activity increases, and maximizes patient ambulatory capability. "SAGE is the latest in a long history of product innovation at CHAD. This exciting new device cements our position as a technological leader in the development of home respiratory products and demonstrates our dedication to providing homecare suppliers and their patients with the widest range of home oxygen products to suit individual needs, preferences and disease conditions. We plan to expand this advanced new platform with additional therapeutic oxygen devices now in development." Jones said that CHAD currently plans to begin initial shipments of the SAGE Oxygen Therapy Device following receipt of FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance, which currently is pending. About CHAD Therapeutics CHAD Therapeutics, Inc. is in the business of developing, producing and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases. For more information, visit www.CHADtherapeutics.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the loss of one or more major customers, increased competition, the introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement which affect home care providers and CHAD's ability to anticipate and respond to technological and economic changes in the home oxygen market. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among homecare providers and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Outlook: Issues and Risks." |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion